Jacques Galipeau

Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada.

Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.

International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States.

Part of BNP Paribas SA, Union de Crédit Pour le Bâtiment SA is a mortgage services provider based in Paris, France.

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

Sanofi Pasteur Ltd. develops, manufactures, and markets vaccines and immunotherapeutic products. It offers vaccines for haemophilus influenza type B (Hib), diphtheria, pertussis, poliomyelitis, tetanus, hepatitis A, influenza, poliomyelitis, rabies, meningococcal disease, typhoid fever, and yellow fever, as well as oncology products for bladder cancers. The company was founded John Gerald FitzGerald in 1914 and is headquartered in Toronto, Canada.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.